Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. GRDN
stocks logo

GRDN

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
2 Analyst Rating
up Image0
Wall Street analysts forecast GRDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRDN is 28.00 USD with a low forecast of 28.00 USD and a high forecast of 28.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
up Image0
Current: 20.280
sliders
Low
28.00
Averages
28.00
High
28.00
up Image0
Current: 20.280
sliders
Low
28.00
Averages
28.00
High
28.00
Truist
Buy
maintain
$25 -> $28
2025-05-19
Reason
Truist
Price Target
$25 -> $28
2025-05-19
maintain
Buy
Reason
Raymond James
John Ransom
Outperform
maintain
$25 -> $28
2025-05-14
Reason
Raymond James
John Ransom
Price Target
$25 -> $28
2025-05-14
maintain
Outperform
Reason
Raymond James analyst John Ransom raised the firm's price target on Guardian Pharmacy to $28 from $25 and keeps an Outperform rating on the shares. The company's Q1 results were ahead of the firm's model on revenue, but $600,000 below on EBITDA due to some pull-forward on Heartland integration costs and a slight miss on seasonality, the analyst tells investors in a research note. This was a solid quarter with no major surprises outside of the small seasonality change, and Raymond James continues to like Guardian for its solid organic and inorganic growth potential, clean balance sheet with dry powder for M&A, and performance of operational execution.
Truist Securities
David Macdonald
Strong Buy
Maintains
$24 → $25
2025-04-11
Reason
Truist Securities
David Macdonald
Price Target
$24 → $25
2025-04-11
Maintains
Strong Buy
Reason
Truist analyst David MacDonald raised the firm's price target on Guardian Pharmacy to $25 from $24 and keeps a Buy rating on the shares as part of a broader research note previewing Q1 results in Healthcare Services and adjusting the firm's models. The sector looks relatively well positioned in a fluid environment given the scaled, largely domestic, attractive free cash flow generating, defensive nature of the group, and while regulatory developments remain an area of focus, the Medicare Advantage final rule reinforced the firm's expectation of a better environment, the analyst tells investors in a research note.
Truist Securities
David Macdonald
Strong Buy
Maintains
$22 → $24
2024-11-15
Reason
Truist Securities
David Macdonald
Price Target
$22 → $24
2024-11-15
Maintains
Strong Buy
Reason
Stephens & Co.
Scott Fidel
Buy
Initiates
$21
2024-10-22
Reason
Stephens & Co.
Scott Fidel
Price Target
$21
2024-10-22
Initiates
Buy
Reason
Truist Securities
David Macdonald
Strong Buy
Initiates
$22
2024-10-21
Reason
Truist Securities
David Macdonald
Price Target
$22
2024-10-21
Initiates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Guardian Pharmacy Services Inc (GRDN.N) is 21.46, compared to its 5-year average forward P/E of 24.20. For a more detailed relative valuation and DCF analysis to assess Guardian Pharmacy Services Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
24.20
Current PE
21.46
Overvalued PE
26.70
Undervalued PE
21.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
14.67
Current EV/EBITDA
13.32
Overvalued EV/EBITDA
15.93
Undervalued EV/EBITDA
13.41

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
1.02
Current PS
0.97
Overvalued PS
1.12
Undervalued PS
0.93

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

GRDN News & Events

Events Timeline

(ET)
2025-06-02
08:24:02
Guardian Pharmacy announces acquisition of Mercury Pharmacy Services
select
2025-05-22 (ET)
2025-05-22
23:57:09
Guardian Pharmacy 7.5M share Secondary priced at $21.00
select
2025-05-21 (ET)
2025-05-21
12:00:43
Guardian Pharmacy falls -17.5%
select
Sign Up For More Events
Sign Up For More Events

News

Preview
8.5
06-10Newsfilter
Guardian Pharmacy of South Carolina Opens New Headquarters in Charleston to Support Statewide Growth

  • Merger and Relocation: Winyah Pharmacy and Preferred Care have merged and rebranded as Guardian Pharmacy of South Carolina, relocating to a new, larger facility in Charleston to enhance their long-term care services across the state.

  • Facility Features and Growth Plans: The new headquarters includes advanced technology and automation for medication preparation, an IV infusion therapy suite, and plans for additional hiring to support ongoing growth and service expansion.

Preview
8.5
06-07Benzinga
Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta

  • Media and Corporate Acquisitions: Byron Allen's Allen Media Group is exploring the sale of its TV stations, while other companies like Jefferies and Sanofi are also involved in significant acquisitions, including PatientPoint and Blueprint Medicines Corporation for $9.1 billion.

  • Bankruptcy and Market Activity: AI startup Builder.ai has filed for Chapter 7 bankruptcy due to overstated sales projections, while Hooters closed several locations amid financial struggles, highlighting ongoing challenges in various sectors.

Preview
8.5
06-02Benzinga
Guardian Pharmacy Strengthens US Footprint With New Seattle-Area Acquisition

  • Guardian Pharmacy Services Expands: Guardian Pharmacy Services, Inc. has entered the Pacific Northwest market by acquiring Mercury Pharmacy Services, enhancing its presence in long-term care pharmacy solutions in Washington state.

  • Operational Continuity and Growth: Mercury will maintain its name and staff while benefiting from Guardian's resources, allowing it to focus on patient care; Guardian now operates over 50 pharmacies nationwide, serving more than 7,000 long-term care facilities.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Guardian Pharmacy Services Inc (GRDN) stock price today?

The current price of GRDN is 20.28 USD — it has decreased -2.55 % in the last trading day.

arrow icon

What is Guardian Pharmacy Services Inc (GRDN)'s business?

Guardian Pharmacy Services, Inc. is a pharmacy services company. The Company provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. Through its locally based pharmacies, the Company utilizes a complex, technology-enabled platform to manage the dispensing and administration of prescriptions to residents of LTCFs over the full prescription lifecycle in order to manage medication risk. Its services include GuardianShield, provider services, and others. Its Guardian Compass platform offers insights to enhance efficiencies for its pharmacies, including proprietary real-time operational dashboards and metrics. Its suite of GuardianShield products offers customer and clinical services that benefit both the residents it serves and their caregivers. It serves assisted living and memory care, hospice care and others.

arrow icon

What is the price predicton of GRDN Stock?

Wall Street analysts forecast GRDN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRDN is 28.00 USD with a low forecast of 28.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Guardian Pharmacy Services Inc (GRDN)'s revenue for the last quarter?

Guardian Pharmacy Services Inc revenue for the last quarter amounts to 329.31M USD, increased 19.57 % YoY.

arrow icon

What is Guardian Pharmacy Services Inc (GRDN)'s earnings per share (EPS) for the last quarter?

Guardian Pharmacy Services Inc. EPS for the last quarter amounts to 0.15 USD, decreased % YoY.

arrow icon

What changes have occurred in the market's expectations for Guardian Pharmacy Services Inc (GRDN)'s fundamentals?

The market is revising Upward the revenue expectations for Guardian Pharmacy Services, Inc. (GRDN) for FY2025, with the revenue forecasts being adjusted by 0.7% over the past three months. During the same period, the stock price has changed by -12.74%.
arrow icon

How many employees does Guardian Pharmacy Services Inc (GRDN). have?

Guardian Pharmacy Services Inc (GRDN) has 3400 emplpoyees as of July 20 2025.

arrow icon

What is Guardian Pharmacy Services Inc (GRDN) market cap?

Today GRDN has the market capitalization of 1.28B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free